ResearcherCentre Hospitalier Universitaire d'AngersActive in the last 2 years
Carole Vitellius
Matched on OpenAlex author ID A5068186041. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic… Co-author DOI 10.1016/j.eclinm.2026.103998↗
- Impact of Driver Mutations on the Evolution of Isolated Metachronous Lung Metastasis of Pancreatic Ductal adenocarcinoma. Co-author DOI 10.1007/s40291-020-00472-9↗
- Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. First author DOI 10.1177/1758835920937949↗
- The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.25560↗
- Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response in Metastatic Pancreatic Adenocarcinoma… Co-author DOI 10.1007/s40261-017-0522-3↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- François‐Xavier Caroli‐Bosc · 3 shared papers, 2017–2020 · strength 0.26
- Paper Impact of Driver Mutations on the Evolution of Isolated Metachronous Lung Metastasis of Pancreatic Ductal adenocarcinom… DOI 10.1007/s40291-020-00472-9↗
- Paper The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic a… DOI 10.18632/oncotarget.25560↗
- Paper Relationship Between the Expression of O6-Methylguanine-DNA Methyltransferase (MGMT) and p53, and the Clinical Response… DOI 10.1007/s40261-017-0522-3↗
- Yves Rinaldi · 1 shared paper, 2026 · strength 0.22
- Frédéric Di Fiore · 1 shared paper, 2026 · strength 0.22
- Anna Pellat · 1 shared paper, 2026 · strength 0.22
- Côme Lepage · 1 shared paper, 2026 · strength 0.22
- Julien Taı̈eb · 1 shared paper, 2026 · strength 0.22
- Simon Pernot · 1 shared paper, 2026 · strength 0.22
- Jean‐Baptiste Bachet · 1 shared paper, 2026 · strength 0.22
- David Tougeron · 1 shared paper, 2026 · strength 0.22
- Christelle d’Engremont · 1 shared paper, 2020 · strength 0.11
- Cindy Neuzillet · 1 shared paper, 2020 · strength 0.11
- Anthony Turpin · 1 shared paper, 2020 · strength 0.11
- Émeric Boisteau · 1 shared paper, 2020 · strength 0.11
- Marc Hilmi · 1 shared paper, 2020 · strength 0.11
- Mathilde Wisniewski · 1 shared paper, 2020 · strength 0.11
- Louis de Mestier · 1 shared paper, 2020 · strength 0.11
- Pascal R. Hammel · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.